August 15, 2020

The Niche

Knoepfler lab stem cell blog

6 min read

Today’s post lists the best stem cell blogs and more generally the top biology blogs as well as websites. Making lists of “the best” of anything is fun yet tricky. However, I feel that it can also serve a purpose as a resource. You might also enjoy these other “top” lists I’ve done including List of 50 stem cell influencers on Twitter to follow in 2019, a list of top stem cell journals, and for fun, Elephant in the lab series: top list of science excuses. Blog-o-rama …Read More

3 min read

The FDA dropped a lengthy, extremely critical warning letter on a supplier of unproven exosome product called EUCYT Laboratories. For broader context, exosome therapy has somehow burst onto the scene when there’s no good data yet in my view to back up its use in the clinic. The FDA is taking notice with letters already sent to others including an untitled letter to Kimera Labs  and on the same date another to a physician who used Kimera products and was at one time amongst Kimera leadership, Doug …Read More

3 min read

My weekly roundups of biomedical news tend to focus on stem cells, but I read more broadly so it’s not just stem cells but also CAR-T cells and a lot more this week. CAR-T cells as senolytics? A team led by Scott Lowe has a new intriguing paper in Nature on using CAR-T cells to target senescent cells. The paper is entitled, “Senolytic CAR T cells reverse senescence-associated pathologies”. The core idea here is that CAR-T cells can be used to get rid of …Read More

5 min read

It was fascinating to read a new JAMA piece by the FDA on unproven stem cell clinics and other regenerative medicine firms. Many of these guys are profiteering off of buzz about exciting, but mostly unproven technologies. While the JAMA opinion piece reiterates the agency’s commitment to evidence-based regenerative medicine, it also makes some other key points, some of which are newer and worth digging into on a deeper level. What’s new here from the FDA? The piece by CBER Director Dr. Peter Marks …Read More